| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0001547 | Antral ovarian follicle growth | Decreases phenotype | PMID:31884101 |
| GO:0003093 | Regulation of glomerular filtration | Affects phenotype | PMID:32645486 |
| GO:0006006 | Glucose metabolic process | Affects phenotype | PMID:25726127 |
| GO:0006590 | Thyroid hormone generation | Increases phenotype | PMID:31093596 |
| GO:0006702 | Androgen biosynthetic process | Decreases phenotype | PMID:31319113 |
| GO:0006909 | Phagocytosis | Decreases phenotype | PMID:30398665 |
| GO:0007628 | Adult walking behavior | Affects phenotype | PMID:37018009 |
| GO:0030335 | Positive regulation of cell migration | Increases phenotype | PMID:35861251 |
| GO:0031324 | Negative regulation of cellular metabolic process | Increases phenotype | PMID:35861251 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:25449125 |
| GO:0033686 | Positive regulation of luteinizing hormone secretion | Increases phenotype | PMID:31015488 |
| GO:0035929 | Steroid hormone secretion | Affects phenotype | PMID:31884101 |
| GO:0035936 | Testosterone secretion | Increases phenotype | PMID:31884101 |
| GO:0035938 | Estradiol secretion | Increases phenotype | PMID:31884101 |
| GO:0035941 | Androstenedione secretion | Increases phenotype | PMID:31884101 |
| GO:0035942 | Dehydroepiandrosterone secretion | Affects phenotype | PMID:28637469; PMID:31884101 |
| GO:0042632 | Cholesterol homeostasis | Affects phenotype | PMID:34425642 |
| GO:0042701 | Progesterone secretion | Increases phenotype | PMID:31884101 |
| GO:0046544 | Development of secondary male sexual characteristics | Decreases phenotype | PMID:24945889; PMID:28637469 |
| GO:0050810 | Regulation of steroid biosynthetic process | Affects phenotype | PMID:31015488 |
| GO:0050890 | Cognition | Decreases phenotype | PMID:25493564; PMID:36746855 |
| GO:0060014 | Granulosa cell differentiation | Affects phenotype | PMID:39752319 |
| GO:0060322 | Head development | Decreases phenotype | PMID:26196298 |
| GO:0060612 | Adipose tissue development | Affects phenotype | PMID:31275917 |
| GO:0072520 | Seminiferous tubule development | Decreases phenotype | PMID:31015488 |
| GO:0090116 | C-5 methylation of cytosine | Decreases phenotype | PMID:35487445 |
| GO:1900017 | Positive regulation of cytokine production involved in inflammatory response | Increases phenotype | PMID:30398665 |
| GO:1990636 | Reproductive senescence | Increases phenotype | PMID:31015488 |
| GO:2000355 | Negative regulation of ovarian follicle development | Increases phenotype | PMID:31015488 |
| GO:2000609 | Regulation of thyroid hormone generation | Affects phenotype | PMID:32464474 |
| GO:2000845 | Positive regulation of testosterone secretion | Increases phenotype | PMID:31015488 |
| GO:2000866 | Positive regulation of estradiol secretion | Increases phenotype | PMID:31015488 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.